Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

The relationship between serum ceruloplasmin,calcium and phosphorus metabolism and secondary hyperprarathyroidism in hemodialysis patients

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Analysis the calcium and phosphorus metabolism disorders in Beijing chronic maintenance hemodialysis patients

[Study of Calcium-Phosphorous Metabolism and Intact Parathyroid Hormone Levels in End Stage Renal Disease Patients].

The relationship between serum ceruloplasmin and iron deficiency,inflammation and peroxidation in hemodialysis patients

The Influence Upon the Levels of Serum Calcium and Parathyroid Hormone by Adjusting Dialysate Calcium Concentration in Hemodialysis Patients

Serum calcium, phosphate, and iPTH levels of dialysis patients in Zhejiang Province

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients

Risk Factors of Parathyroid Dysfunction in Elderly Patients with Chronic Kidney Disease Undergoing Hemodialysis.

Mineral and Bone Disorder in Chinese Dialysis Patients: a Multicenter Study

Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study

Changes of Calcium and Phosphate Metabolism in Maintenance Hemodialysis Patients: Survey in a Dialysis Center

Clinical Analysis of Persistent Hypercalcemia with Osteoporosis Caused by Tertiary Hyperparathyroidism after Kidney Transplantation

Influence of Low Calcium Dialysate on Serum Parathyroid Hormone, Calcium and Phosphate in Patients under Hemodialysis

Plasma Metabolite Biomarkers Related to Secondary Hyperparathyroidism and Parathyroid Hormone.

Cross-sectional Study of Calcium Phosphate Product and Intact Parathyroid Hormone Levels in Predialysis and Postdialysis Patients with Stage 5 Chronic Kidney Disease

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

The present status and the related factors of abnormal calcium- phosphorous metabolism in mainte-nance hemodialysis patients

Disorders of calcium and phosphorus metabolism and influence factors in peritoneal dialysis patients.

PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients

Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration